Axonics Modulation Technologies Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $58.85
- Today's High:
- $61.84
- Open Price:
- $61.18
- 52W Low:
- $46.57
- 52W High:
- $79.92
- Prev. Close:
- $61.29
- Volume:
- 748208
Company Statistics
- Market Cap.:
- $2.42 billion
- Book Value:
- 11.507
- Revenue TTM:
- $295.93 million
- Operating Margin TTM:
- -10.53%
- Gross Profit TTM:
- $197.67 million
- Profit Margin:
- -15.64%
- Return on Assets TTM:
- -3.27%
- Return on Equity TTM:
- -8.9%
Company Profile
Axonics Modulation Technologies Inc had its IPO on 2018-10-31 under the ticker symbol AXNX.
The company operates in the Healthcare sector and Medical Devices industry. Axonics Modulation Technologies Inc has a staff strength of 610 employees.
Stock update
Shares of Axonics Modulation Technologies Inc opened at $61.18 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $58.85 - $61.84, and closed at $59.38.
This is a -3.12% slip from the previous day's closing price.
A total volume of 748,208 shares were traded at the close of the day’s session.
In the last one week, shares of Axonics Modulation Technologies Inc have increased by +2.38%.
Axonics Modulation Technologies Inc's Key Ratios
Axonics Modulation Technologies Inc has a market cap of $2.42 billion, indicating a price to book ratio of 5.8046 and a price to sales ratio of 12.2448.
In the last 12-months Axonics Modulation Technologies Inc’s revenue was $295.93 million with a gross profit of $197.67 million and an EBITDA of $-19647000. The EBITDA ratio measures Axonics Modulation Technologies Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Axonics Modulation Technologies Inc’s operating margin was -10.53% while its return on assets stood at -3.27% with a return of equity of -8.9%.
In Q1, Axonics Modulation Technologies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 45.9%.
Axonics Modulation Technologies Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Axonics Modulation Technologies Inc’s profitability.
Axonics Modulation Technologies Inc stock is trading at a EV to sales ratio of 11.8264 and a EV to EBITDA ratio of -43.3642. Its price to sales ratio in the trailing 12-months stood at 12.2448.
Axonics Modulation Technologies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $665.69 million
- Total Liabilities
- $66.17 million
- Operating Cash Flow
- $694000.00
- Capital Expenditure
- $794000
- Dividend Payout Ratio
- 0%
Axonics Modulation Technologies Inc ended 2024 with $665.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $665.69 million while shareholder equity stood at $576.61 million.
Axonics Modulation Technologies Inc ended 2024 with $15.74 million in deferred long-term liabilities, $66.17 million in other current liabilities, 5000.00 in common stock, $-383512000.00 in retained earnings and $96.58 million in goodwill. Its cash balance stood at $240.11 million and cash and short-term investments were $357.06 million. The company’s total short-term debt was $1,557,000 while long-term debt stood at $0.
Axonics Modulation Technologies Inc’s total current assets stands at $469.67 million while long-term investments were $0 and short-term investments were $116.96 million. Its net receivables were $40.20 million compared to accounts payable of $14.74 million and inventory worth $66.07 million.
In 2024, Axonics Modulation Technologies Inc's operating cash flow was $694000.00 while its capital expenditure stood at $794000.
Comparatively, Axonics Modulation Technologies Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $59.38
- 52-Week High
- $79.92
- 52-Week Low
- $46.57
- Analyst Target Price
- $78.91
Axonics Modulation Technologies Inc stock is currently trading at $59.38 per share. It touched a 52-week high of $79.92 and a 52-week low of $79.92. Analysts tracking the stock have a 12-month average target price of $78.91.
Its 50-day moving average was $56.01 and 200-day moving average was $56.98 The short ratio stood at 6.27 indicating a short percent outstanding of 0%.
Around 81.7% of the company’s stock are held by insiders while 10326.1% are held by institutions.
Frequently Asked Questions About Axonics Modulation Technologies Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.